Loading
companiesCompany
Pathos AI
Pathos AI trains multimodal artificial intelligence models on millions of cancer patients' genomic, imaging, text and outcome records to choose which experimental drugs to develop and which patients to test them in. It has licensed a TROP2/HER3 bispecific antibody-drug conjugate and an oestrogen receptor degrader, and raised a 365 million dollar Series D in 2025.
Overview
Pathos AI is an AI-enabled, clinical-stage oncology biotech. Its PATHOS platform draws on millions of oncology records integrating genomics, transcriptomics, imaging, text and longitudinal outcomes, and is building what the company describes as the largest multimodal foundation model in oncology to select assets, design trials and discover biomarkers. In August 2026 it licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, from Alphamab Oncology ($125 million upfront, up to $2,093 million in milestones) and agreed a co-exclusive licence to take the oestrogen receptor PROTAC degrader AZD4241 into the clinic for ER-positive breast cancer. In May 2026 it took a majority stake in DeuterOncology (MET inhibitor). Pathos raised a $365 million Series D in May 2025 at a post-money valuation of about $1.6 billion.
Headquarters
New York, NY, US
Funding
All startupsGrowth stage
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series D · Post-money valuation about $1.6 billion, May 2025; investors not named in the release. | 2025 | $365M | pathos.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Growth stage
Website
Notes
top- The Series D release dateline is New York, NY rather than Chicago; Chicago may be an operating base but is not stated on fetched pages. Series D investors were not named. The AstraZeneca counterparty for AZD4241 is inferred from the asset code on the company news page, not stated in the fetched text. Tempus partnership not mentioned on fetched pages. companyType set to biotech because the company develops drugs; it also fits ai-software.
Similar pages
- TreatmentENV-501
Shares HER3, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- PersonRegina Barzilay
Shares AI-driven drug & target discovery, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- CompanyPrelude Therapeutics
Shares PROTACs & molecular glues (targeted protein degradation), HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors.
- TrialPANKU-Esophagus01 (BL-B01D1-305)
Shares HER3, Bispecific ADC.
- CompanyImagene AI
Shares Pathology & radiology foundation models, MET, Non-small-cell lung cancer.
- TechnologyChemistry42 and Pharma.AI (Insilico)
Shares AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyMerlin (Stanford abdominal CT vision-language model)
Shares Pathology & radiology foundation models, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow.
- TreatmentTilatamig samrotecan
Shares Bispecific ADC, MET, Non-small-cell lung cancer.